Comparing Impact of Panel Composition on Tumor Mutational Burden Calculation

Video

Nicholas Bevins, MD, PhD, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology Annual Meeting and Expo.

Nicholas Bevins, MD, PhD, a postgraduate resident at the University of California, San Diego, discusses the results from an in silico comparison of frequently used next-generation sequencing panels. The analysis aimed to identify the impact of the panel composition on tumor mutational burden (TMB) calculations. Results from the analysis were presented in a poster at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo.

Clinicians at the University of California, San Diego, questioned what the difference was between different lab-based panels and Foundation Medicine panels, so investigators sought to compare how the different panel compositions may impact TMB.

Related Videos
Related Content